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Background/Aims: The risk for colonoscopic postpolypec-
tomy bleeding (PPB) in patients with chronic liver disease 
(CLD) remains unclear. We determined the incidence and 
risk factors for colonoscopic PPB in patients with CLD, espe-
cially those with liver cirrhosis. Methods: We retrospectively 
reviewed the medical records of patients with CLD who un-
derwent colonoscopic polypectomy at Seoul National Univer-
sity Hospital between 2011 and 2014. The study endpoints 
were immediate and delayed PPB. Results: A total of 1,267 
consecutive patients with CLD were included in the study. Im-
mediate PPB occurred significantly more often in the Child-
Pugh (CP) B or C cirrhosis group (17.5%) than in the CP-A 
(6.3%) and chronic hepatitis (4.6%) groups (p<0.001). More-
over, the incidence of delayed PPB in the CP-B or C cirrhosis 
group (4.4%) was significantly higher than that in the CP-A 
(0.7%) and chronic hepatitis (0.2%) groups (p<0.001). The 
independent risk factors for immediate PPB were CP-B or C 
cirrhosis (p=0.011), a platelet count <50,000/μL (p<0.001), 
3 or more polyps (p=0.017), endoscopic mucosal resection 
or submucosal dissection (p<0.001), and polypectomy per-
formed by trainees (p<0.001). The independent risk factors 
for delayed PPB were CP-B or C cirrhosis (p=0.009), and pol-
yps >10 mm in size (p=0.010). Conclusions: Patients with 
CP-B or C cirrhosis had an increased risk for bleeding fol-
lowing colonoscopic polypectomy. (Gut Liver 2020;14:755-
764)
Key Words: Hepatitis, chronic; Chronic liver disease; Colonos-
copy; Liver cirrhosis; Postpolypectomy bleeding
INTRODUCTION
Colonoscopic procedures for removal of colorectal adenoma-
tous polyps are effective for primary and secondary prevention 
of colorectal cancers, but are associated with a risk for serious 
adverse events, such as postpolypectomy bleeding (PPB). PPB is 
the most common adverse event following a colonoscopic pol-
ypectomy, and its frequency ranges from 0.2% to 6.1%.1-5 PPB 
may occur immediately after colonoscopic polypectomy or can 
be delayed up to 30 days after the procedure. A literature review 
identified, old age, underlying comorbidities such as hyperten-
sion, cardiovascular disease and chronic kidney disease, large-
sized polyps, and polyps located in the right-sided colon as 
known risk factors for colonoscopic PPB.3,6-9
Patients with chronic liver disease (CLD) have a tendency to 
bleed due to a disruption of coagulation factor synthesis in the 
liver, and this disruption is often accompanied by thrombocyto-
penia and portal hypertension.10,11 Previous studies indicated that 
patients with CLD are more prone to bleeding following an inva-
sive procedure such as surgery or liver biopsy.12,13 However, the 
risk of bleeding following colonoscopic resection of colorectal 
polyps in patients with a CLD such as chronic hepatitis or liver 
cirrhosis (LC) has not been fully evaluated. This study investigat-
ed the incidence and risk factors for PPB, including immediate 
and delayed PPB, in patients with a CLD, and especially LC.
MATERIALS AND METHODS
1. Patients
From January 2011 to December 2014, the medical records of 
all patients with a CLD (e.g., chronic hepatitis or LC) who under-
went a colonoscopic polypectomy at Seoul National University 
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Hospital were reviewed retrospectively. Patients with CLD were 
defined as those who had displayed evidence of hepatic insult 
for >6 months. The etiologies of CLD were identified by review-
ing each patient’s medical history, serologic laboratory findings 
including viral and autoimmune markers, and abdominal imag-
ing results, including abdominal ultrasonography, computed 
tomography, magnetic resonance imaging, and/or liver biopsy. 
Patients with viral hepatitis were identified with serologic mark-
ers. Patients with alcoholic liver disease were identified with 
history of excessive alcohol consumption within 6 months (more 
than 60 g/day for male and 40 g/day for female) and exclusion 
of viral hepatitis, systemic autoimmune diseases, and metabolic 
diseases. Nonalcoholic fatty liver disease was defined as the 
presence of fatty liver in abdominal imaging, a history of daily 
alcohol intake less than 20 g/day and exclusion of viral hepa-
titis, systemic autoimmune diseases, and metabolic diseases.14,15 
The diagnosis of LC was based on abdominal imaging findings, 
liver histology and/or clinical signs of portal hypertension such 
as the presence of ascites, esophageal or gastric varices, and 
hepatic encephalopathy.16-18 The patient information collected 
for the study included data regarding age, sex, laboratory find-
ings such as serum albumin, total bilirubin, prothrombin time, 
and platelet counts, Child-Pugh (CP) scores, number, size, and 
location of the polyps, underlying diseases (diabetes mellitus, 
hypertension, dyslipidemia, coronary heart disease, cerebrovas-
cular disease, and chronic kidney disease), and whether the pa-
tient was taking concomitant antiplatelet and/or anticoagulant 
medications such as aspirin, clopidogrel, ticagrelor, cilostazol, 
heparin, low molecular weight heparin, warfarin, or a new oral 
anticoagulant. Patients with platelet count less than 20,000/μL 
were excluded from the colonoscopic procedure. Patients who 
received transfusions of fresh frozen plasma or platelet concen-
trates before the procedures were included and the corrected 
results of blood tests following transfusions were collected. Gen-
erally, patients taking antiplatelet and/or anticoagulant agents 
were advised to hold the medication as follows; aspirin for 7 
days, clopidogrel, ticagrelor, and cilostazol for 5 days, heparin 
for 6 hours, low molecular weight heparin for 12 hours, warfa-
rin for 3 to 5 days, and new oral anticoagulant for 1 to 2 days 
before the colonoscopic procedures. Patients who discontinued 
the medication less than the advised interval were identified 
as those with concomitant medication. LC severity was classi-
fied into categories of CP class A to C, based on each patient’s 
CP score (CP-A, 5–6 points; CP-B, 7–9 points; CP-C, 10–15 
points).19 This study adhered to the tenets of the Declaration of 
Helsinki. As the study did not include personal identifiers and 
was of a retrospective observational nature, informed consent 
was waived, and the study protocol was approved by the Seoul 
National University Hospital Institutional Review Board (IRB 
number: H-1807-042-957).
2. Procedures 
Colonoscopy was performed with a standard colonoscope (CF 
H260AL; Olympus, Tokyo, Japan). In general, 2 L of polyethyl-
ene glycol solution was used for bowel preparation. Colorectal 
polyps detected during the procedure were removed by one of 
the following methods: cold forceps polypectomy, endoscopic 
mucosal resection (EMR), or endoscopic submucosal dissection 
(ESD). EMR was performed to resect polyps >4 mm in diameter, 
and ESD was indicated for polyps >20 mm in diameter, for 
which resection with snare EMR would be difficult. The inject-
and-cut technique was used for EMR. Epinephrine solution 
diluted with saline containing indigo carmine was administered 
as a subcutaneous injection given with a NM-4U-1 needle 
(Olympus). After elevating the polyp from the mucosa, a wire 
snare (SD-12L/U-1; Olympus) was used to enclose and grasp 
the polyp, and a cutting and coagulating electrical current was 
applied. For ESD, the area surrounding the polyp was marked 
with a dual knife (KD-650U; Olympus) that administered electri-
cal coagulation (20W, VIO 300D; Erbe, Tübingen, Germany). 
Epinephrine diluted with saline containing indigo carmine was 
injected into the area, and consequently, the polyp was resected 
and submucosa was dissected using a dual knife.20 All colono-
scopic procedures were performed by five expert endoscopists 
and 38 colonoscopy trainees. Expert endoscopists were defined 
as experienced endoscopists who performed >1,000 colonosco-
pies.
14,648 Patients excluded:
Diagnostic colon scopyo (52.5%)
13,233 Patients with endoscopic
resection of colorectal polyps (47.4%)
27,881 Patients underwent colonoscopic
procedures (2011 to 2014)
1,267 Patients with CLD (4.5%)
453 Patients with chronic hepatitis (1.6%)
700 Patients with CP-A cirrhosis (2.5%)
100 Patients with CP-B cirrhosis (0.4%)
14 Patients with CP-C cirrhosis (0.05%)
11,966 Patients excluded:
Patients without CLD (42.9%)
Fig. 1. Study flowchart.
CLD, chronic liver disease; CP, 
Child-Pugh.
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CP class A (n=700) CP class B (n=100) CP class C (n=14)
Age, yr 61.2±8.5 62.4±9.0 60.9±10.9 51.8±7.1 <0.001
Male sex 317 (70.0) 515 (73.6) 69 (69.0) 11 (78.6) 0.471
Serum albumin, g/dL 4.37±0.37 4.17±0.42 3.28±0.61 2.54±0.51 <0.001
Serum total bilirubin, mg/dL 0.99±0.45 1.16±0.54 2.59±3.03 11.06±10.84 <0.001
Prothrombin time, INR 1.033±0.470 1.091±0.127 1.281±0.290 2.200±1.130 <0.001
PLT count, ×103/µL 204.9±57.1 138.8±63.4 85.9±47.9 84.9±42.1 <0.001
Patients with PLT <50,000/μL 0 34 (4.9) 16 (16.0) 0 <0.001
CP score 5.2±0.4 7.5±0.7 11.6±1.4 <0.001
Cause of CLD <0.001
   HBV 313 (69.1) 518 (74.0) 61 (61.0) 9 (64.3)
   HCV 62 (13.7) 73 (10.4) 16 (16.0) 0 
   Alcoholic 40 (8.8) 25 (3.6) 9 (9.0) 4 (28.6)
   NAFLD 22 (4.9) 22 (3.1) 6 (6.0) 0 
   Autoimmune 2 (0.4) 10 (1.4) 1 (1.0) 0 
   Cryptogenic 14 (3.1) 52 (7.4) 7 (7.0) 1 (7.1)
Polyp no. 2.3±2.0 2.3±1.9 2.6±2.2 1.5±0.8 <0.001
Polyp size, mm 5.5±3.8 6.2±4.8 6.8±4.7 6.2±5.9 <0.001
Polyp ≥10 mm 55 (12.1) 117 (16.7) 20 (2.0) 4 (28.6) 0.045
Method of polypectomy 0.132
   CFP 205 (45.3) 305 (43.6) 39 (39.0) 10 (71.4)
   EMR or ESD 248 (54.7) 395 (56.4) 61 (61.0) 4 (28.6)
Location of polyp 0.001
   Proximal 188 (41.5) 261 (37.3) 33 (33.0) 1 (7.1)
   Distal 122 (26.9) 231 (33.0) 30 (30.0) 11 (78.6)
   Mixed 143 (31.6) 208 (29.7) 37 (37.0) 2 (14.3)
Endoscopist 0.195
   Expert 127 (28.0) 165 (23.6) 21 (21.0) 2 (14.3)
   Trainee 326 (72.0) 535 (76.4) 79 (79.0) 12 (85.7)
Underlying disease
   DM 102 (22.5) 181 (25.6) 32 (32.0) 4 (28.6) 0.219
   Hypertension 157 (34.7) 199 (28.4) 21 (21.0) 0 0.002
   Dyslipidemia 107 (23.6) 50 (7.1) 0 0 <0.001
   CHD 28 (6.2) 24 (3.4) 0 0 0.014
   CVD 13 (2.9) 11 (1.6) 1 (1.0) 0 0.354
   CKD 42 (9.3) 45 (6.4) 13 (13.0) 2 (14.3) 0.059
Concomitant medication
   Aspirin 43 (9.5) 26 (3.7) 0 0 <0.001
   Clopidogrel 6 (1.3) 3 (0.4) 0 0 0.259
   Cilostazol 2 (0.4) 3 (0.4) 0 0 0.919
Data are presented as mean±SD or number (%).
CP, Child-Pugh; INR, international normalized ratio; PLT, platelet; CLD, chronic liver disease; HBV, hepatitis B virus; HCV, hepatitis C virus; 
NAFLD, nonalcoholic fatty liver disease; CFP, cold forceps polypectomy; EMR, endoscopic mucosal resection; ESD, endoscopic submucosal dissec-
tion; DM, diabetes mellitus; CHD, coronary heart disease; CVD, cerebrovascular disease; CKD, chronic kidney disease.
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3. Definitions
The study endpoints were immediate and delayed PPB follow-
ing colonoscopic resection for colorectal polyps. Immediate PPB 
was defined as development of bleeding from a polypectomy 
site during the colonoscopic procedure, for which hemostasis 
with hemoclipping, electrocauterization, and/or epinephrine 
injection was required. Delayed PPB was defined as the presen-
tation of melena or hematochezia within 30 days of the colono-
scopic procedure, with the symptoms requiring hospitalization 
or a hemostasis procedure.21,22 Clinical outcomes related to PPB 
following the colonoscopic removal of colorectal polyps, includ-
ing need for colonoscopic hemostasis, surgical intervention, and 
mortality, were also evaluated.
4. Statistical analysis 
All numerical values are expressed as the mean±standard 
deviation, or number (percent). Continuous variables were com-
pared using the Student t-test. Categorical variables, both two-
way and ordinal categories, were compared using the chi-square 
test. Independent risk factors for PPB were analyzed using the 
logistic regression models. Adjusted odds ratios (ORs) and 95% 
confidence intervals (CIs) were calculated to estimate the effect 
of the variables in multivariate logistic regression models. A 
p-value <0.05 was considered statistically significant. All sta-
tistical analyses were performed using IBM SPSS Statistics for 
Windows, version 23.0 (IBM Corp., Armonk, NY, USA).
RESULTS
1. Demographics
From January 2011 to December 2014, colonoscopic pro-
cedures were performed in 27,881 patients at Seoul National 
University Hospital, and among them, 13,223 patients (47.4%) 
underwent endoscopic resection of colorectal polyps. Among 
the patients treated for colorectal polyps, 1,267 consecutive pa-
tients with accompanying CLD were enrolled in this study (Fig. 
1). Baseline characteristics of the study population are summa-
rized in Table 1. The study population comprised 453 (35.8%) 
patients with chronic hepatitis, 700 (55.2%) with CP-A cirrhosis, 
100 (7.9%) with CP-B, and 14 (1.1%) with CP-C, respectively. 
The mean serum albumin level (g/dL) was 4.37±0.37 in patients 
with chronic hepatitis, 4.17±0.42 in patients with CP-A cirrho-
sis, 3.28±0.61 in patients with CP-B cirrhosis, and 2.54±0.51 in 
patients with CP-C cirrhosis (p<0.001). The mean serum total 
bilirubin level and the mean prothrombin time in the CP-C cir-
rhosis group was significantly higher than those in the chronic 
hepatitis, CP-A, and CP-B cirrhosis groups (both p<0.001). The 
mean serum albumin level and mean platelet count in CP-C cir-
rhosis group was significantly lower than those in the chronic 
hepatitis, CP-A, and CP-B cirrhosis groups (both p<0.001). 
Among the study population, 50 (3.9%) patients with CP-A or B 
cirrhosis showed a platelet count less than 50,000/μL (Supple-
mentary Table 1). The mean CP score was 5.2±0.4 in CP-A cir-
rhosis, 7.5±0.7 in CP-B cirrhosis, and 11.6±1.4 in CP-C cirrhosis 
(p<0.001).
The mean number of polyps was 2.3±2.0 in chronic hepatitis, 
2.3±1.9 in CP-A cirrhosis, 2.6±2.2 in CP-B cirrhosis, and 1.5±0.8 
in CP-C cirrhosis, respectively (p<0.001). The mean polyp size 
was 5.5±3.8 mm in chronic hepatitis, 6.2±4.8 mm in CP-A cir-
rhosis, 6.8±4.7 mm in CP-B cirrhosis, and 6.2±5.9 mm in CP-C 
cirrhosis (p<0.001), respectively. The proportion of proximal 
colon polyps was significantly higher in the chronic hepatitis 
group compared to the cirrhosis groups, but the distal loca-
tion was significantly associated with the CP-C cirrhosis. With 
regard to underlying diseases, the prevalence of hypertension 
and dyslipidemia were significantly higher among patients with 
chronic hepatitis than among patients with CP-A, B, and C cir-
rhosis (p=0.002 and p<0.001, respectively). The chronic hepatitis 
group used significantly higher percentage of aspirin compared 
to the CP-A, B, and C cirrhosis groups (p<0.001). None of the 
study participants were taking an anticoagulant such as low 
molecular weight heparin, warfarin, or new oral anticoagulant.
2. Incidence and clinical outcomes of PPB 
Among the 1,267 patients with CLD, 95 (7.5%) experienced 
PPB. The incidence of PPB was significantly higher among 
patients with CP-B or C cirrhosis (21.9%) than among patients 
with chronic hepatitis (4.9%) or CP-A cirrhosis (6.9%) (p<0.001). 
Immediate PPB occurred in 85 patients (6.7%). The incidence of 
immediate PPB was significantly higher among patients with 
CP-B or C cirrhosis (17.5%) than among patients with chronic 
hepatitis (4.6%) or CP-A cirrhosis (6.3%) (p<0.001) (Table 2). All 
of the patients with immediate PPB improved following colo-
noscopic electrocauterization, epinephrine spraying, hot biopsy 
forceps coagulation, and/or hemoclipping.
A total of 11 patients (0.9%) experienced delayed PPB, and 
the incidence of delayed PPB was also significantly higher 
among patients with CP-B or C cirrhosis (4.4%) than among pa-
tients those with chronic hepatitis (0.2%) or CP-A cirrhosis (0.7%) 
(p<0.001) (Table 2). All patients with delayed PPB underwent 
EMR or ESD for resection of polyps. Among the 11 patients 






p-valueCP class A 
(n=700)
CP class B, C 
(n=114)
PPB (%)
   Total 22 (4.9) 48 (6.9) 25 (21.9) <0.001
   Immediate 21 (4.6) 44 (6.3) 20 (17.5) <0.001
   Delayed 1 (0.2) 5 (0.7) 5 (4.4) <0.001
PPB, postpolypectomy bleeding; CP, Child-Pugh.
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Univariate analysis Multivariate analysis
OR (95% CI) p-value OR (95% CI) p-value
Sex
   Male 60 (6.6) 1 (reference)
   Female 25 (7.0) 1.076 (0.663–1.745) 0.767
Age, yr 0.99 (0.967–1.104) 0.425
Platelet count
   ≥50,000/μL 70 (5.9) 1 (reference) 1 (reference)
   <50,000/μL 14 (27.5) 6.038 (3.118–11.690) <0.001 6.617 (3.045–14.382) <0.001
Chronic liver disease <0.001 0.011
   CH 21 (4.6) 1 (reference) 1 (reference)
   CP class A 44 (6.3) 1.38 (0.809–2.353) 0.237 0.977 (0.554–1.722) 0.935
   CP class B, C 20 (17.5) 4.377 (2.281–8.399) <0.001 2.483 (1.204–5.122) 0.014
No. of polyp 
   <3 36 (4.0) 1 (reference) 1 (reference)
   ≥3 49 (13.0) 3.529 (2.253–5.527) <0.001 2.055 (1.136–3.717) 0.017
Size of polyp, mm 
   <10 59 (5.5) 1 (reference) 1 (reference)
   ≥10 26 (13.3) 2.623 (1.609–4.278) <0.001 1.526 (0.875–2.663) 0.137
Method of polypectomy
   CFP 16 (2.9) 1 (reference) 1 (reference)
   EMR or ESD 25 (6.3) 3.665 (2.102–6.388) <0.001 3.303 (1.694–6.437) <0.001
Location of polyp <0.001 0.013
   Proximal 18 (3.7) 1 (reference) 1 (reference)
   Distal 20 (5.1) 1.381 (0.720–2.649) 0.331 1.445 (0.720–2.898) 0.300
   Mixed 47 (12.1) 3.54 (2.020–6.203) <0.001 1.981 (1.021–3.845) 0.043
Endoscopist
   Expert 12 (3.8) 1 (reference) 1 (reference)
   Trainee 73 (7.7) 2.097 (1.123–3.915) 0.020 3.462 (1.786–6.709) <0.001
Underlying diseases
   DM 27 (8.5) 1.419 (0.882–2.282) 0.149
   Hypertension 24 (6.4) 0.924 (0.567–1.506) 0.751
   Dyslipidemia 5 (3.2) 0.424 (0.169–1.062) 0.067
   CHD 1 (1.9) 0.264 (0.036–1.934) 0.190
   CVD 2 (8.0) 0.824 (0.191–3.556) 0.796
   CKD 8 (7.8) 1.203 (0.564–2.566) 0.633
Concomitant medication
   Aspirin 2 (2.9) 0.401 (0.097–1.666) 0.209
   Clopidogrel 0 1.000
   Cilostazol 0 1.000
PPB, postpolypectomy bleeding; OR, odds ratio; CI, confidence interval; CH, chronic hepatitis; CP, Child-Pugh; CFP, cold forceps polypectomy; 
EMR, endoscopic mucosal resection; ESD, endoscopic submucosal dissection; DM, diabetes mellitus; CHD, coronary heart disease; CVD, cerebro-
vascular disease; CKD, chronic kidney disease.
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Table 4. Risk Factors for Delayed Postpolypectomy Bleeding 
Variable
Incidence of  
delayed PPB (%)
Univariate analysis Multivariate analysis
OR (95% CI) p-value OR (95% CI) p-value
Sex
   Male 9 (1.0) 1 (reference)
   Female 2 (0.6) 0.568 (0.122–2.644) 0.471
Age, yr 0.957 (0.899–1.019) 0.173
Platelet count
   ≥50,000/μL 9 (0.8) 1 (reference) 1 (reference)
   <50,000/μL 2 (4.1) 5.342 (1.124–25.388) 0.035 5.354 (0.779–36.823) 0.088
Chronic liver disease 0.002 0.009
   CH 1 (0.2) 1 (reference) 1 (reference)
   CP class A 5 (0.7) 3.252 (0.379–27.925) 0.282 2.748 (0.265–28.446) 0.397
   CP class B, C 5 (4.4) 20.734 (2.398–179.283) 0.006 19.715 (1.736–223.875) 0.016
No. of polyp 
   <3 3 (0.3) 1 (reference) 1 (reference)
   ≥3 8 (2.1) 6.386 (1.685–24.203) 0.006 2.918 (0.658–12.936) 0.159
Size of polyp, mm 
   <10 2 (0.2) 1 (reference) 1 (reference)
   ≥10 9 (4.6) 25.725 (5.515–119.998) <0.001 8.274 (1.662–41.205) 0.010
Method of polypectomy
   CFP 0 NA
   EMR or ESD 11 (1.6) NA 1.000
Location of polyp 0.519
   Proximal 4 (0.8) 1 (reference)
   Distal 2 (0.5) 0.611 (0.111–3.353) 0.571
   Mixed 5 (1.3) 1.555 (0.415–5.831) 0.513
Endoscopist
   Expert 4 (0.4) 1 (reference) 1 (reference)
   Trainee 7 (2.2) 0.186 (0.054–0.638) 0.008 0.306 (0.074–1.255) 0.100
Underlying diseases
   DM 0 1.000
   Hypertension 1 (0.3) 0.234 (0.030–1.835) 0.167
   Dyslipidemia 1 (0.6) 0.705 (0.090–5.546) 0.740
   CHD 0 1.000
   CVD 2 (8.3) 11.903 (2.435–58.180) 0.002 4.703 (0.282–78.295) 0.281
   CKD 2 (2.0) 2.569 (0.548–12.052) 0.232
Concomitant medication
   Aspirin 0 1.000
   Clopidogrel 1 (11.1) 15.600 (1.781–136.628) 0.013 9.567 (0.152–601.475) 0.285
   Cilostazol 0 1.000
PPB, postpolypectomy bleeding; OR, odds ratio; CI, confidence interval; CH, chronic hepatitis; CP, Child-Pugh; CFP, cold forceps polypectomy; 
EMR, endoscopic mucosal resection; ESD, endoscopic submucosal dissection; DM, diabetes mellitus; CHD, coronary heart disease; CVD, cerebro-
vascular disease; CKD, chronic kidney disease. 
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with delayed PPB, 10 (90.9%) required colonoscopic hemostasis, 
including electrocauterization, hot biopsy forceps coagulation, 
and/or hemoclipping. The other one patient refused any addi-
tional colonoscopic procedure, and the bleeding spontaneously 
subsided during hospitalization. No patient required surgical 
intervention, and no mortality related to PPB was found. 
3. Independent risk factors for PPB 
Our univariate analysis showed that immediate PPB was sig-
nificantly associated with CP-B or C cirrhosis (p<0.001), a plate-
let count < 50,000/μL (p<0.001), 3 or more polyps (p<0.001), 
a polyp size ≥10 mm (p<0.001), mixed location of polyps 
(p<0.001), EMR or ESD (p<0.001), and polypectomy performed 
by trainees (p=0.020) respectively. The multivariate analysis re-
vealed that the independent risk factors for immediate PPB were 
CP-B or C cirrhosis (adjusted OR, 2.483; 95% CI, 1.204 to 5.122; 
p=0.011), a platelet count <50,000/μL (adjusted OR, 6.617; 95% 
CI, 3.045 to 14.382; p<0.001), 3 or more polyps (adjusted OR, 
2.055; 95% CI, 1.136 to 3.717; p=0.017), EMR or ESD (adjusted 
OR, 3.303; 95% CI, 1.694 to 6.437; p<0.001), and polypectomy 
performed by trainees (adjusted OR, 3.462; 95% CI, 1.786 to 
6.709; p<0.001) (Table 3).
In terms of the risk factors for delayed PPB, the univariate 
analysis showed that delayed PPB was significantly associated 
with CP-B or C cirrhosis (p=0.002), a platelet count <50,000/
μL (p=0.035), 3 or more polyps (p=0.006), a polyp size ≥10 mm 
(p<0.001), polypectomy performed by experts (p=0.008), the 
presence of cerebrovascular disease (p=0.002), and clopidogrel 
use (p=0.013), respectively. The multivariate analysis showed 
that CP-B or C cirrhosis (adjusted OR, 19.715; 95% CI, 1.736 to 
223.875; p=0.009), and a polyp size ≥10 mm (adjusted OR, 8.274; 
95% CI, 1.662 to 41.205; p=0.010) were independent risk factors 
for delayed PPB (Table 4).
DISCUSSION
To the best of our knowledge, this is the largest cohort study 
to evaluate the incidence and risk factors for PPB following the 
colonoscopic resection of colorectal polyps in patients with CLD. 
Among the 1,267 patients with CLD, 114 patients with CP-B 
or C cirrhosis underwent endoscopic treatment for colorectal 
polyps. As a result, the overall incidence of PPB among patients 
with CLD was 7.5%, which is higher than that incidence in the 
general population (0.2% to 6.1%).23,24 In this study, however, 
the incidence of PPB among patients with chronic hepatitis was 
4.9%, which is comparable with the risk for bleeding following 
colonoscopic polypectomy in the general population. Previous 
studies concerning the risk for bleeding following colonoscopic 
polypectomy have also shown that chronic hepatitis is not a 
significant risk factor for PPB.3,21 Patients with chronic hepatitis 
have decreased levels of most procoagulant factors, but the lev-
els of naturally occurring anticoagulants such as antithrombin 
and protein C are also decreased in patients with chronic hepa-
titis, resulting in a balanced coagulant system similar to that 
found in healthy individuals.25
In this study, however, LC significantly increased the risk 
for both immediate and delayed PPB, according to CP scores. 
The incidence of delayed PPB among patients with CP-B or C 
cirrhosis was approximately 20-fold higher that that among 
patients with chronic hepatitis (4.4%). This is consistent with 
results from a previous retrospective study of 152 patients with 
CLD. That study reported an increased incidence of delayed 
PPB (defined as >1 episode of hematochezia 6 hours to 30 days 
after colonoscopic polypectomy) among patients with LC when 
compared to patients with chronic hepatitis (13.8% vs 4.2%).26 
However, the incidence of delayed PPB in cases of CP-B or 
C cirrhosis was relatively lower in our study due to the dif-
ferent definition of delayed PPB. In terms of immediate PPB, 
a retrospective study of 30 patients with LC showed that LC-
related variables did not significantly increase the risk for im-
mediate PPB, but that result was due to the small sample size.21 
However, a retrospective study of 89 patients with LC indicated 
that patients with CP-B or C cirrhosis were at a higher risk for 
immediate PPB.27 A recent retrospective study of 307 patients 
with LC, which included 44 patients with CP-B or C cirrhosis, 
reported that the overall incidence of immediate PPB was 7.5%, 
with a higher incidence of immediate PPB among CP-B or C LC 
patients (up to 13.6%). Furthermore, the presence of ascites or 
esophageal varices significantly increased the risk for immedi-
ate PPB.28 In our largest cohort study that included 114 patients 
with CP-B or C cirrhosis, the overall incidence of immediate 
PPB among CP-A cirrhosis patients was 6.3%; however, CP-B or 
C cirrhosis patients were at an approximately 3-fold higher risk 
for immediate PPB when compared to CP-A cirrhosis patients, 
which is consistent with the results of previous studies. LC, and 
especially decompensated cirrhosis, undoubtedly increases the 
risk for bleeding.25 This bleeding tendency among patients with 
cirrhosis is a product of several factors. Portal hypertension 
causes hemodynamic alterations, and high sialic acid concentra-
tions hinder fibrinogen function. A bacterial infection or renal 
dysfunction may become superimposed on these abnormalities, 
and thereby aggravate a bleeding tendency.29-31 Taken together, 
patients with LC should be made aware of their increased risk 
for bleeding following a colonoscopic polypectomy, prior to un-
dergoing the procedure. Moreover, any presentation of immedi-
ate or delayed PPB should be closely monitored in patients with 
LC, and especially in patients with CP-B or C cirrhosis. 
Our current study showed that the risk for immediate PPB 
was significantly increased among CLD patients with a platelet 
count <50,000/μL. Among our patients with CP-B, C cirrhosis, 
and a platelet count <50,000/μL, the incidence of immediate 
PPB was 31.3% (data not shown). Immediate PPB is related to 
a dysfunction of primary hemostasis, which involves platelet 
aggregation and coagulation factors.32,33 Patients with decom-
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pensated cirrhosis have a diminished ability to synthesize co-
agulation factors in the liver, and exhibit thrombocytopenia and 
thrombocytopathy due to platelet sequestration, thrombopoietin 
deficiency, and low grade disseminated intravascular coagula-
tion, all of which contribute to hemostatic abnormalities.34,35 In 
vitro studies have shown that thrombin generation, assessed as 
endogenous thrombin potential, can be secured with a platelet 
count ≥50,000/μL,36 indicating the necessity for a platelet trans-
fusion prior to performing any invasive procedure such as a 
colonoscopic polypectomy in CP-B or C cirrhosis patients.
This study showed that multiple polyps, mixed proximal and 
distal colon polyps, colonoscopic polypectomies conducted via 
EMR or ESD, and those performed by trainees, were also inde-
pendent risk factors for immediate PPB in patients with CLD. 
Previous studies have also identified several polyp-associated 
risk factors for immediate PPB; polyp number, size, and mor-
phology are all well-established polyp-associated risk factors.1 
Polypectomy performed with an advanced technique37 and the 
experience of the endoscopist38 have also been identified as risk 
factors for immediate PPB, which correlates with our findings. 
Increased risk for immediate PPB in polyps with mixed loca-
tion may owe to the multiple number of polyps. Therefore, CLD 
patients, and especially those with CP-B or C cirrhosis and risk 
factors for immediate PPB associated with certain characteristics 
of their polyps and advanced procedures, should be considered 
as being at a higher risk for immediate bleeding prior to under-
going a colonoscopic polypectomy.
In this study, a polyp size ≥10 mm and CP-B or C cirrhosis 
were identified as independent risk factors for delayed PPB. The 
adjusted risks for delayed bleeding as determined by a polyp 
size ≥10 mm was approximately 1.526-fold higher in patients 
with CLD, respectively. Delayed PPB may be related not only to 
direct damage of the blood vessels which perfuse the resected 
polyp, but also to some insufficiencies resulting from the tissue 
healing process or vascular regeneration.39 Cirrhosis induces 
defects of primary hemostasis and delayed tissue healing that 
result from cirrhosis-associated immune dysfunction and an 
increased level of systemic inflammation,40 which may result in 
an increased risk for delayed bleeding after colonoscopic polyp-
ectomy. Polyp size is a well-established risk factor for delayed 
PPB, as larger polyps would cause delays in tissue healing and 
vascular regeneration.39 Thus, close monitoring for delayed 
bleeding in large-sized polyps in patients with CLD, and espe-
cially cirrhosis, would be needed.
Our study has some limitations that should be mentioned. 
First, it was a single center, retrospective study, and conse-
quently might have been affected by selection bias. Second, 
even though it was the largest cohort study of patients with LC, 
the effect of CP-C cirrhosis compared to CP-A and B cirrhosis 
on the risk for PPB could not be determined due to the small 
sample size. Third, data on shape and histologic findings of the 
polyps were not available. Pedunculated shape or advanced 
neoplasm might lead to the additive risk of PPB in the patients 
with CLD. Fourth, Whether the incidence of PPB in the pa-
tients with CLD is significantly higher compared to the general 
population could not be evaluated, because the study popula-
tion was limited to those with CLD in this study. Fifth, patients 
with a platelet count less than 50,000/μL were included in this 
retrospective study. The American Society for Gastrointestinal 
Endoscopy recommends a threshold of 50,000/μL before colo-
noscopic polypectomy despite a lack of evidence.41 We aimed 
to define the optimal cutoff of platelet counts for colonoscopic 
polypectomy as well as the high-risk group for PPB in the CLD 
population at risk of bleeding. Finally, some patients with LC 
required anticoagulation therapy for managing their portal vein 
thrombosis; however, any additive risk for PPB resulting from 
anticoagulant use among patients with CLD could not be evalu-
ated in this study. Further prospective studies are required to 
determine how anticoagulant use affects the risk for bleeding in 
patients with a CLD and undergo colonoscopic polypectomy.
In conclusion, we found that patients with CP-B or C cirrho-
sis had an increased risk for bleeding following a colonoscopic 
resection for colorectal polyps when compared to patients with 
chronic hepatitis. Therefore, patients with CP-B or C cirrhosis, 
and especially those with thrombocytopenia, or multiple or 
large-sized polyps resected by EMR or ESD, should be carefully 
monitored for any presentation of PPB.
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